BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 31673960)

  • 1. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature.
    Halyabar O; Mehta J; Ringold S; Rumsey DG; Horton DB
    Paediatr Drugs; 2019 Dec; 21(6):469-492. PubMed ID: 31673960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance.
    Horton DB; Onel KB; Beukelman T; Ringold S
    J Rheumatol; 2017 Mar; 44(3):352-360. PubMed ID: 28148696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
    McMahan R; Balfe LM; Greene L
    J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors.
    Gieling J; van den Bemt B; Hoppenreijs E; Schatorjé E
    Pediatr Rheumatol Online J; 2022 Dec; 20(1):109. PubMed ID: 36471348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
    Chang CY; Meyer RM; Reiff AO
    Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of inactive disease while off disease-modifying anti-rheumatic drugs seems to influence flare rates in juvenile idiopathic arthritis: an observational retrospective study.
    Aires PP; Terreri MTRA; Silva VBM; Vieira MM; Len CA
    Acta Reumatol Port; 2021; 46(2):120-125. PubMed ID: 34226433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flares After Withdrawal of Biologic Therapies in Juvenile Idiopathic Arthritis: Clinical and Laboratory Correlates of Remission Duration.
    Simonini G; Ferrara G; Pontikaki I; Scoccimarro E; Giani T; Taddio A; Meroni PL; Cimaz R
    Arthritis Care Res (Hoboken); 2018 Jul; 70(7):1046-1051. PubMed ID: 28973842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When to stop medication in juvenile idiopathic arthritis.
    Abel D; Weiss PF
    Curr Opin Rheumatol; 2023 Sep; 35(5):265-272. PubMed ID: 37139831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial.
    Gerss J; Tedy M; Klein A; Horneff G; Miranda-Garcia M; Kessel C; Holzinger D; Stanevica V; Swart JF; Cabral DA; Brunner HI; Foell D
    Ann Rheum Dis; 2022 Jul; 81(7):990-997. PubMed ID: 35260388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.
    Foell D; Wulffraat N; Wedderburn LR; Wittkowski H; Frosch M; Gerss J; Stanevicha V; Mihaylova D; Ferriani V; Tsakalidou FK; Foeldvari I; Cuttica R; Gonzalez B; Ravelli A; Khubchandani R; Oliveira S; Armbrust W; Garay S; Vojinovic J; Norambuena X; Gamir ML; García-Consuegra J; Lepore L; Susic G; Corona F; Dolezalova P; Pistorio A; Martini A; Ruperto N; Roth J;
    JAMA; 2010 Apr; 303(13):1266-73. PubMed ID: 20371785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach.
    Castillo-Vilella M; Giménez N; Tandaipan JL; Quintana S; Modesto C
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):130. PubMed ID: 34419078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis? A best-worst scaling survey.
    Currie GR; Groothuis-Oudshoorn CGM; Twilt M; Kip MMA; IJzerman MJ; Benseler SM; Swart JF; Vastert SJ; Wulffraat NM; Yeung R; Marshall DA
    Clin Rheumatol; 2023 Aug; 42(8):2173-2180. PubMed ID: 37202606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
    Davies R; Gaynor D; Hyrich KL; Pain CE
    Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Guidelines on biologic drugs for the treatment of children with juvenile idiopathic arthritis (JIA)].
    Bukovac LT; Vidović M; Lamot L; Perica M; Harjacek M;
    Reumatizam; 2013; 60(1):57-66. PubMed ID: 24003687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.
    Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ
    Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What to Expect When Systemic Treatment in Juvenile Idiopathic Arthritis Is Withdrawn?
    Nieto-González JC; Garulo DC; Boteanu A; Trives-Folguera L; García-Fernández A; Navarro PG; Robledillo JCL; Monteagudo-Saéz I
    J Rheumatol; 2023 Oct; 50(10):1326-1332. PubMed ID: 37527855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologics in juvenile idiopathic arthritis: a narrative review.
    Vanoni F; Minoia F; Malattia C
    Eur J Pediatr; 2017 Sep; 176(9):1147-1153. PubMed ID: 28725955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Which Children with Juvenile Idiopathic Arthritis Will Not Attain Early Remission with Conventional Treatment: Results from the ReACCh-Out Cohort.
    Guzman J; Henrey A; Loughin T; Berard RA; Shiff NJ; Jurencak R; Huber AM; Oen K; Gerhold K; Feldman BM; Scuccimarri R; Houghton K; Chédeville G; Morishita K; Lang B; Dancey P; Rosenberg AM; Barsalou J; Bruns A; Watanabe Duffy K; Benseler S; Duffy CM; Tucker LB;
    J Rheumatol; 2019 Jun; 46(6):628-635. PubMed ID: 30647178
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.